Higgins Jack 4

What Happened Jack Higgins, Chief Scientific Officer of Immunome, reported the disposition of 9,438 shares of Immunome common stock on April 2, 2026. The shares were sold at $21.64 per share for a total proceeds of approximately $204,238. The filing lists the transaction as a sale (S) and indicates it was executed via an open-market/private sale.

Key Details

• Transaction date and price: April 2, 2026 — 9,438 shares sold at $21.64/share (total ≈ $204,238).
• Transaction code: S (sale).
• Plan: Sale was effected under a prearranged Rule 10b5-1 trading plan adopted December 19, 2025 (Footnote F1).
• Custodial note: The shares reported were held in a custodial account for the reporting person’s child; Higgins disclaims beneficial ownership of these shares (Footnote F2). The shares are also subject to a lock-up agreement entered December 15, 2025.
• Shares owned after transaction: Not specified on the Form 4; beneficial ownership of these specific shares is disclaimed.
• Filing timeliness: Report filed April 3, 2026 for a April 2, 2026 transaction — appears timely (Form 4s are generally due within two business days).

Context This was a sale under a 10b5-1 plan, which typically means the trade was pre-scheduled and not necessarily based on current company-specific nonpublic information. The custodial-account footnote indicates these shares relate to a minor’s account and the reporting person disclaims beneficial ownership, which can affect how investors interpret the insider’s economic exposure. Sales are routine insider activity and do not, by themselves, indicate management’s view of the company’s prospects.